Answers from the Lab

Joshua Bornhorst, Ph.D., explains how Mayo Clinic Laboratories' labile copper assay (Mayo ID: LBCS) improves upon standard blood tests for Wilson's disease. The new test measures not just overall copper but also the fraction of copper that is bioavailable, or labile bound.

(00:32)
Can you tell us a little bit about yourself and your background?
 
(01:33)
 Could you give us a brief overview of this assay?
 
(02:47)
 Which patients should have this testing, and when should it be performed?
 
(03:48)
 How would the results be used in patient care?

What is Answers from the Lab?

A Mayo Clinic curated podcast sharing Mayo Clinic knowledge and advancements on the state of testing, science, and people who are making it happen behind the scenes.